ArticleFrontiers in medicine2026
A CD30-positive variant of intravascular large B-cell lymphoma presenting as diffuse interstitial lung disease and generalized lymphadenopathy: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive malignancy defined by the proliferation of neoplastic B-cells within the vascular lumen. While the disease can affect multiple organs, commonly manifesting as skin lesions, neurological deficits, or hepatosplenomegaly, it usually spares the lymph nodes and rarely presents as diffuse interstitial lung disease (DILD). We report a 62-year-old man admitted with recurrent fever and progressive dyspnea. Chest computed tomography revealed extensive bilateral interstitial lung disease, with ultrasonography showing generalized lymphadenopathy with preserved architecture. Although initial therapy led to a favorable response, the patient subsequently relapsed. Lymph node biopsy confirmed IVLBCL, characterized by intravascular and intrasinusoidal lymphoma cell infiltration with well-preserved nodal architecture. Notably, the tumor cells showed diffuse strong CD30 expression (~70%), a rare finding potentially linked to the unusual clinical presentation. Conclusion: This case demonstrates that IVLBCL can present with diffuse interstitial lung disease and generalized lymphadenopathy, expanding its recognized phenotypic spectrum. It may represent a variant with CD30-mediated nodal homing and immune activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.